7 Rue des Chasseurs Ardennais
|Mr. Frank Hazevoets||MD, CEO, CFO & Director||N/A||N/A||1966|
|Mr. Vincent Bille||Head of Technical Operations||N/A||N/A||N/A|
|Attorney M. Grégory Nihon||Compliance Officer & Gen. Sec.||N/A||N/A||N/A|
|Mr. François Gary||Bus. Devel. & Marketing Director||N/A||N/A||N/A|
|Ms. Marie Pierre Beaumont||Head of HR||N/A||N/A||N/A|
|Ms. Béatrice De Vos||Chief Medical Officer||7.5k||N/A||N/A|
|Mr. Philippe Ghem||Head of Commercial Operations & Licensing||N/A||N/A||N/A|
|Mr. Rémy von Frenckell||Head of Clinical Devel.||N/A||N/A||N/A|
|Ms. Martine Draguet||Head of Regulatory Affairs & Quality Assurance||N/A||N/A||N/A|
DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.
DMS Imaging SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.